Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01754623 · ClinicalTrials.gov registry record · Phase 2
GTX-RT in Borderline Resectable Pancreatic Cancer
A Phase 2 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT01754623 is a Phase 2 study that was terminated before completion, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 9 participants.
The verdict
NCT01754623, a Phase 2 study, was terminated before completion, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
The purpose of this study is to find out if a program of intensive chemotherapy with gemcitabine, docetaxel and capecitabine followed by an advanced form of focused radiation aimed at participant's tumor followed by more chemotherapy can increase the chances that the participant's pancreatic tumor can be removed completely.
Interventions
- DRUG Docetaxel
- DRUG Capecitabine
- DRUG Gemcitabine
- RADIATION Stereotactic body radiation therapy (SBRT)
- OTHER Restaging review after radiation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2013-02 |
| Est. Completion | 2014-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01754623
The ClinicalTrials.gov registry entry for NCT01754623 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Docetaxel is the first listed.
NCT01754623 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01754623 about?
NCT01754623 is a clinical study titled "GTX-RT in Borderline Resectable Pancreatic Cancer". The purpose of this study is to find out if a program of intensive chemotherapy with gemcitabine, docetaxel and capecitabine followed by an advanced form of focused radiation aimed at participant's tumor followed by more chemotherapy can increase the chances that the participant's pancreatic tumor c...
What is the current status of trial NCT01754623?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2013-02. Estimated completion is 2014-10.
What interventions are being tested in trial NCT01754623?
The interventions under investigation include: Docetaxel (DRUG), Capecitabine (DRUG), Gemcitabine (DRUG), Stereotactic body radiation therapy (SBRT) (RADIATION), Restaging review after radiation (OTHER).
Who is sponsoring clinical trial NCT01754623?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.